PMC:7463108 / 76560-76918 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T739","span":{"begin":97,"end":100},"obj":"Body_part"},{"id":"T740","span":{"begin":147,"end":151},"obj":"Body_part"},{"id":"T741","span":{"begin":214,"end":217},"obj":"Body_part"}],"attributes":[{"id":"A739","pred":"fma_id","subj":"T739","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A740","pred":"fma_id","subj":"T740","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A741","pred":"fma_id","subj":"T741","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"To date, no clinical studies have assessed whether opioid interactions with R5- or R4-preferring HIV strains differentially impact the severity of HAND. However, the findings from preclinical studies indicate that HIV-1 strain-specific differences are critical determinants in shaping both the timing and pattern of neurotoxic interactions with opioid drugs."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T177","span":{"begin":76,"end":78},"obj":"Disease"},{"id":"T178","span":{"begin":83,"end":85},"obj":"Disease"}],"attributes":[{"id":"A177","pred":"mondo_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/MONDO_0016654"},{"id":"A178","pred":"mondo_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/MONDO_0015439"}],"text":"To date, no clinical studies have assessed whether opioid interactions with R5- or R4-preferring HIV strains differentially impact the severity of HAND. However, the findings from preclinical studies indicate that HIV-1 strain-specific differences are critical determinants in shaping both the timing and pattern of neurotoxic interactions with opioid drugs."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T254","span":{"begin":352,"end":357},"obj":"Chemical"}],"attributes":[{"id":"A80037","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"To date, no clinical studies have assessed whether opioid interactions with R5- or R4-preferring HIV strains differentially impact the severity of HAND. However, the findings from preclinical studies indicate that HIV-1 strain-specific differences are critical determinants in shaping both the timing and pattern of neurotoxic interactions with opioid drugs."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2607","span":{"begin":214,"end":219},"obj":"Species"},{"id":"2608","span":{"begin":97,"end":100},"obj":"Species"},{"id":"2609","span":{"begin":316,"end":326},"obj":"Disease"}],"attributes":[{"id":"A2607","pred":"tao:has_database_id","subj":"2607","obj":"Tax:11676"},{"id":"A2608","pred":"tao:has_database_id","subj":"2608","obj":"Tax:12721"},{"id":"A2609","pred":"tao:has_database_id","subj":"2609","obj":"MESH:D020258"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"To date, no clinical studies have assessed whether opioid interactions with R5- or R4-preferring HIV strains differentially impact the severity of HAND. However, the findings from preclinical studies indicate that HIV-1 strain-specific differences are critical determinants in shaping both the timing and pattern of neurotoxic interactions with opioid drugs."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1046","span":{"begin":0,"end":152},"obj":"Sentence"},{"id":"T1047","span":{"begin":153,"end":358},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To date, no clinical studies have assessed whether opioid interactions with R5- or R4-preferring HIV strains differentially impact the severity of HAND. However, the findings from preclinical studies indicate that HIV-1 strain-specific differences are critical determinants in shaping both the timing and pattern of neurotoxic interactions with opioid drugs."}